Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
BD (BDX) Q4 Earnings In-Line With Estimates, Margins Contract
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in all its segments and both geographic regions in the fiscal fourth quarter.
Here's Why You Should Retain Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX), led by growing demand for WATCHMAN FLX devices and upbeat guidance.
Alcon (ALC) Unveils New Progress in Presbyopia Correcting IOLs
by Zacks Equity Research
Alcon's (ALC) Clareon Vivity IOL highlights proven results and high levels of patient satisfaction. It will offer a similar halo profile compared with a monofocal IOL.
Surmodics (SRDX) Q4 Earnings Top Estimates, Revenues Up Y/Y
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust segmental revenues.
Inspire Medical (INSP) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the third quarter.
Wall Street Analysts See a 25.28% Upside in Abbott (ABT): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 25.3% upside potential for Abbott (ABT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Inogen (INGN) Q3 Earnings Miss Estimates, Revenues Down Y/Y
by Zacks Equity Research
Despite higher international business-to-business sales and rental revenues, Inogen's (INGN) overall third-quarter results reflect soft performances.
Accuray (ARAY) Q1 Earnings In-Line With Estimates, Revenues Top
by Zacks Equity Research
Accuray (ARAY) reports a solid fiscal first quarter top line on the back of robust Product revenues.
Charles River's (CRL) Q3 Earnings Beat, Margins Decline
by Zacks Equity Research
Charles River's (CRL) RMS organic revenue growth is primarily driven by research model services, particularly the Insourcing Solutions business.
DaVita (DVA) Q3 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
DaVita's (DVA) robust segmental revenues drive its third-quarter performance.
Masimo (MASI) Q3 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
Masimo's (MASI) overall third-quarter results reflect soft performance despite strength in the Hearables category.
Globus Medical (GMED) Q3 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Globus Medical's (GMED) legacy business continues to drive share growth across its U.S. spine and trauma portfolios in the third quarter.
Here's Why You Should Retain Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN), led by its strong global presence.
Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
Zimmer Biomet (ZBH) gains from solid strategic execution and increasing traction in innovations in the third quarter.
OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall third-quarter results reflect soft performances.
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q3
by Zacks Equity Research
Myriad Genetics' (MYGN) third-quarter 2023 revenues increase year over year, driven by strong testing volume improvement across all its businesses.
Shockwave Medical (SWAV) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
Insulet (PODD) Q3 Earnings Beat, 2023 Sales Growth View Up
by Zacks Equity Research
Insulet's (PODD) third-quarter 2023 revenues increase year over year as a result of continued high demand for Omnipod 5.
Inari Medical (NARI) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inari Medical's (NARI) third-quarter results benefit from strong product adoption and geographical performances.
AMN Healthcare (AMN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall third-quarter performance.
Cardinal Health (CAH) Beats on Q1 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) first-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.
Stryker (SYK) Q3 Earnings Beat on Strong Segmental Result
by Zacks Equity Research
Stryker's (SYK) third-quarter earnings reflect strong performance across its segments and geographies. However, unfavorable currency movement hurts sales growth, and rising costs affect margins.
Fresenius Medical (FMS) Q3 Earnings Miss, Operating Margin Up
by Zacks Equity Research
Fresenius Medical's (FMS) third-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Penumbra (PEN) Q3 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
Penumbra's (PEN) vascular and neuro product categories continue to show encouraging growth trends.